A Novel Treatment for Constipation-Predominant Irritable Bowel Syndrome Using Padma®Lax, a Tibetan Herbal Formula

Digestion ◽  
2002 ◽  
Vol 65 (3) ◽  
pp. 161-171 ◽  
Author(s):  
Sarah Sallon ◽  
Eran Ben-Arye ◽  
Roni Davidson ◽  
Haim Shapiro ◽  
Gary Ginsberg ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Formula ◽  
Novel Treatment ◽  
Irritable Bowel

scholarly journals Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data

2012 ◽  
Vol 2012 (dec13 1) ◽  
pp. bcr-2012-007223-bcr-2012-007223 ◽  
Author(s):  
E. F. Sprake ◽  
V. A. Grant ◽  
B. M. Corfe
Keyword(s):  
Irritable Bowel Syndrome ◽  
Vitamin D3 ◽  
Critical Analysis ◽  
Single Case ◽  
Novel Treatment ◽  
Irritable Bowel

scholarly journals JCM-16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS-Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Hong-Yan Qin ◽  
Hai-Tao Xiao ◽  
Fung-Ping Leung ◽  
Zhi-Jun Yang ◽  
Justin C. Y. Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Analgesic Effect ◽  
Tryptophan Hydroxylase ◽  
Herbal Formula ◽  
Mechanical Stimuli ◽  
Visceral Hyperalgesia ◽  
Cell Hyperplasia ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

The present study aimed to investigate the analgesic effect of JCM-16021, a revised traditional Chinese herbal formula, on postinflammatory irritable bowel syndrome (PI-IBS) in rats. The trinitrobenzene sulfonic (TNBS) acid-induced PI-IBS model rats were orally administrated with different doses of JCM-16021 (1.2, 2.4, and 4.8 g/kg/d) for 14 consecutive days. The results showed that JCM-16021 treatment dose-dependently attenuated visceral hyperalgesia in PI-IBS rats. Further, the colonic enterochromaffin (EC) cell number, serotonin (5-HT) content, tryptophan hydroxylase expression, and mechanical-stimuli-induced 5-HT release were significantly ameliorated. Moreover, the decreased levels of mucosal cytokines in PI-IBS, especially the helper T-cell type 1- (Th1-) related cytokine TNF-α, were also elevated after JCM-16021 treatment. These data demonstrate that the analgesic effect of JCM-16021 on TNBS-induced PI-IBS rats may be medicated via reducing colonic EC cell hyperplasia and 5-HT availability.

scholarly journals The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiaohui Guo ◽  
Meiling Xuan ◽  
Huan Zheng ◽  
Shumin Qin ◽  
Haomeng Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Outcome Measures ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Life Questionnaire ◽  
Herbal Formula ◽  
Efficacy And Safety ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

Abstract Background Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evaluate the efficacy and safety of HXZQ for IBS-D patients. Methods This is a double-blind, randomized, placebo-controlled trial. The 212 eligible patients with IBS-D will be randomly assigned to receive either HXZQ oral liquid or a placebo, at a 1:1 ratio, for 4 weeks with a 4-week follow-up period. Adequate relief will be the primary outcome measures. IBS symptom severity score, IBS quality-of-life questionnaire, EQ-5D-5L, and Chinese medicine symptom questionnaire will be the secondary outcome measures. Discussion This trial aims to demonstrate the efficacy and safety of HXZQ for IBS-D, which is expected to be an effective IBS-D treatment. Trial registration The trial was registered with the Chinese Clinical Trial Registry, ChiCTR1900026837. Registered on 24 October 2019.

Sign in / Sign up

Export Citation Format

Share Document